Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV111, a CD19 Directed in situ CAR T for Hematologic Malignancies
31 juil. 2024 07h00 HE
|
Umoja Biopharma, Inc.
- UB-VV111 is potentially the first in situ generated CD19 chimeric antigen receptor (CAR)-T cell therapy to be evaluated in humans in the hematology setting - - First patient expected to be dosed by...
CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet
10 juil. 2024 08h00 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet
CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
14 mai 2024 16h05 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Phase 1 onCARlytics solid tumour trial advances to combination arm treatment
11 mars 2024 11h39 HE
|
Imugene Limited
Phase 1 trial of CD19 oncolytic virotherapy drug candidate onCARlytics cleared its first cohort within the intratumoral monotherapy arm of the study.
CARGO Therapeutics Announces Pricing of Initial Public Offering
09 nov. 2023 20h07 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Announce Pricing of IPO
Teneobio Announces US FDA Clearance of Investigational New Drug Application for TNB-486 and the Initiation of Phase I Clinical Studies in Patients with B-cell Malignancies
01 oct. 2020 08h00 HE
|
TeneoBio, Inc
NEWARK, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc. and its affiliate TeneoTwo, Inc. announced today that their investigational new drug application (IND) for TNB-486, a bispecific...
Triumvira to Present Corporate Update at the Bloom Burton & Co. Healthcare Investor Conference
25 avr. 2016 08h30 HE
|
Triumvira Immunologics Inc.
HAMILTON, ON and HACKENSACK, NJ --(Marketwired - April 25, 2016) - Triumvira Immunologics Inc. today announced that its President and Chief Executive Officer Tony Fiorino, MD, PhD, will present a...